Vaccinex Inc.

5.98+0.0100+0.17%Vol 48.40K1Y Perf 19.56%
Aug 10th, 2020 10:55 DELAYED
BID5.90 ASK5.96
Open6.00 Previous Close5.97
Pre-Market- After-Market-
 - -%  - -%
Target Price
22.00 
Analyst Rating
Strong Buy 1.00
Potential %
267.89 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Market Cap99.54M 
Earnings Rating
Buy
Price Range Ratio 52W %
30.63 
Earnings Date
12th Aug 2020

Today's Price Range

5.856.17

52W Range

3.2212.23

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-5.69%
1 Month
65.83%
3 Months
59.20%
6 Months
-3.86%
1 Year
19.56%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
VCNX5.980.01000.17
AAPL444.800.35000.08
GOOG1 479.61-14.8800-1.00
MSFT207.47-5.0100-2.36
XOM44.080.64001.47
WFC24.83-0.2400-0.96
JNJ148.51-0.0900-0.06
FB261.65-6.7900-2.53
GE6.630.23003.59
JPM100.701.32001.33
Earnings HistoryEstimateReportedSurprise %
Q01 2020-0.49-0.458.16
Q04 2019-0.52-0.3826.92
Q03 2019-0.53-0.56-5.66
Q02 2019-0.70-0.77-10.00
Q01 2019-0.68-0.79-16.18
Q03 2018-0.58-0.93-60.34
----
----
Earnings Per EndEstimateRevision %Trend
6/2020 QR-0.510.00-
9/2020 QR-0.460.00-
12/2020 FY-1.774.84Positive
12/2021 FY-1.692.87Positive
Next Report Date12th Aug 2020
Estimated EPS Next Report-0.51
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume48.40K
Shares Outstanding16.65M
Trades Count195
Dollar Volume291.15K
Avg. Volume246.07K
Avg. Weekly Volume180.02K
Avg. Monthly Volume1.42M
Avg. Quarterly Volume532.39K

Vaccinex Inc. (NASDAQ: VCNX) stock closed at 5.97 per share at the end of the most recent trading day (a -7.44% change compared to the prior day closing price) with a volume of 292.47K shares and market capitalization of 99.54M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 44 people. Vaccinex Inc. CEO is Maurice Zauderer.

The one-year performance of Vaccinex Inc. stock is 19.56%, while year-to-date (YTD) performance is 23.09%. VCNX stock has a five-year performance of %. Its 52-week range is between 3.22 and 12.23, which gives VCNX stock a 52-week price range ratio of 30.63%

Vaccinex Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of 289.11, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -329.52%, a ROC of -% and a ROE of 138.22%. The company’s profit margin is -%, its EBITDA margin is -6 904.00%, and its revenue ttm is $404.00 Thousand , which makes it $0.02 revenue per share.

Of the last four earnings reports from Vaccinex Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.51 for the next earnings report. Vaccinex Inc.’s next earnings report date is 12th Aug 2020.

The consensus rating of Wall Street analysts for Vaccinex Inc. is Strong Buy (1), with a target price of $22, which is +267.89% compared to the current price. The earnings rating for Vaccinex Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Vaccinex Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Vaccinex Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 46.15, ATR14 : 0.74, CCI20 : -36.51, Chaikin Money Flow : -0.24, MACD : 0.46, Money Flow Index : 20.08, ROC : -20.93, RSI : 50.97, STOCH (14,3) : 11.47, STOCH RSI : 0.00, UO : 48.50, Williams %R : -88.53), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Vaccinex Inc. in the last 12-months were: Albert D. Friedberg (Buy at a value of $9 122 341), Jacob B. Frieberg (Buy at a value of $199 996), John E. Leonard (Option Excercise at a value of $12 832), Maurice Zauderer (Buy at a value of $499 996)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Vaccinex Inc.

Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its lead product candidate VX15 is in clinical development for the treatment of NSCLC, osteosarcoma and Huntington's disease and additional product candidates VX5 and VX25 are in earlier stages of development.

CEO: Maurice Zauderer

Teplephone: +1 585 271-2700

Address: 1895 Mount Hope Avenue, Rochester 14620, NY, USA

Number of employees: 44

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

54%46%

Bearish Bullish

50%50%

Bearish Bullish

42%58%

News

Stocktwits